API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market: Industry Analysis and Forecast (2023-2029)

Global API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market size was valued at US$ 2.96 Bn. in 2022 and the total revenue is expected to grow at a CAGR of 6.1% through 2023 to 2029, reaching nearly US$ 4.49 Bn.
API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market Overview:
The manufacture of active pharmaceutical ingredients (APIs) is a vital component of drug research, and an active pharmaceutical ingredient is any chemical or combination of substances utilised in a finished pharmaceutical product (FPP) (API). APIs such as Chondroitin Sulphate, Hyaluronic Acid, and Pancreatin are included in the market analysis. Any drug's completed dose is made up of active pharmaceutical components and excipients. In a drug dose, an excipient is an inactive ingredient. Chondroitin sulphate is a nutritional supplement and an important component of cartilage, whereas hyaluronic acid is a key component of therapeutic solutions for osteoarthritis, skin disorders, and cosmetic purposes. Chondroitin sulphate is also utilised in aquaculture feed.To know about the Research Methodology :- Request Free Sample Report

Though market forecasting through 2029 is based on real output, demand and supply of 2022, 2022 numbers are also estimated on real numbers published by key players as well all important players across the world. Market forecasting till 2029 is done based on past data from 2018 to 2022 with the impact of global lock down on the market in 2021 and 2022.
COVID-19 Influence on the Global Market:
Despite the fact that the COVID-19 pandemic has resulted in significant losses for businesses and industries across the field, the healthcare sector is expected to grow at a rapid pace despite the ongoing COVID-19 scenario. During the ongoing public health crisis, demand for chondroitin sulphate is expected to remain largely unaffected, since the production and processing of chondroitin sulphate is expected to continue without interruption. Furthermore, during the pandemic, sales of chondroitin sulfate-containing medications, particularly among people with osteoarthritis, are expected to rise. This can be due to patients' uncertainties about the current circumstances as well as anxieties about movement and transportation restrictions.
API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market Dynamics:
The rising prevalence of chronic diseases such as osteoarthritis and gastrointestinal diseases around the world is propelling the global (API) chondroitin sulphate, hyaluronic acid, and pancreatin market forward. The global (API) chondroitin sulphate, hyaluronic acid, and pancreatin market is also growing because to an increase in clinical studies on various grade products used for the treatment of various ailments.

Furthermore, an increase in drug master files (DMF) submissions by Indian and Chinese businesses, as well as availability for different applications, are driving the global API (Chondroitin Sulfate, Hyaluronic Acid, and Pancreatin) market forward.

An assortment of commercial and potential applications of chondroitin sulphate have arisen in recent years as a result of the increased number of research and development activities connected to the substance. However, stakeholders in the current API (Chondroitin Sulfate, Hyaluronic Acid, and Pancreatin) market landscape are expected to focus on other ways that will facilitate to gain an advantage, due to mounting environmental issues and the effect of currently deployed animal extractive processes on the environment.

At present, chondroitin sulphate is also being employed as a food supplement, biopolymer in materials for regenerative medicine, and more due to which, the API (Chondroitin Sulfate, Hyaluronic Acid and Pancreatin) market is predicted to display a constant increase during the assessment period. Market companies have moved their focus toward excellent manufacturing practise as a result of environmental concerns along with religious issues among consumers in various locations (GMP). Another key reason that is expected to boost the growth of the global API (Chondroitin Sulfate, Hyaluronic Acid, and Pancreatin) market during the forecast period is the use of metabolically modified microbes and customised fermentation techniques.
Segment Analysis:
The Global API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market is segmented by Product, Type, Application, and End Users.

Based on the Product, the market is segmented into Chondroitin Sulfate, Hyaluronic Acid, and Pancreatin. Hyaluronic Acid segment is expected to hold the largest market shares of xx% by 2029. The increasing number of studies and the high level of interest in HA from many sectors are fuelling the segment's growth. HA is an unbranched polymer that belongs to the glycosaminoglycans (GAGs) family of heteropolysaccharides found in epithelial, connective, and neural tissue of vertebrates. Non-circulatory cosmetic procedures, such as hyaluronic acid injectors, are driving the market. Many health benefits of hyaluronic acid include moisture retention, faster wound healing, joint pain reduction, reduced dry eyes and inflammation, and bone strength protection.

The act of ageing, cigarette smoke, and pollution can all reduce the amount of hyaluronic acid in human skin. This reduction can be avoided with the usage of hyaluronic acid-based vitamins and serums, allowing people to enhance their skin. These factors have led the Hyaluronic acid segment to rise, resulting in growing market.

Based on the End Users, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, and Others. Pharmaceutical Companies and Biotechnology Companies are expected to grow rapidly at a CAGR of xx% and xx% during the forecast period 2023-2029. Chronic illness outbreaks, pandemics, and the quest for tailored medications are all driving up demand for pharma and biotech. The US is the world's largest pharmaceutical market and a global leader in biopharmaceutical research. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), American companies undertake the majority of global pharmaceutical research and development and own the intellectual property rights to the majority of new drugs. The US market for pharmaceuticals is the world's largest free-market market, with a favourable patent and regulatory framework.

The biopharmaceutical industry is primarily reliant on research conducted by small businesses and university institutions, which is either bought by larger corporations that can commercialise the medicines or funded independently.
Regional Insights:
North America dominates the Global market during the forecast period 2023-2029. North America is expected to hold the largest market share of xx% in 2029. The rising prevalence of osteoarthritis, as well as the growing geriatric population, are the factors for all of this. Several government efforts have been established in recent years to help complement the region's biopharmaceuticals industry growth. The market's growth is also influenced by well-established healthcare infrastructure and accessibility. Market growth has been fuelled by leading players' investments. In the market for lymphedema diagnostic imaging systems, the usage of technologically advanced diagnostic imaging systems is continuously increasing. These are the major drivers that boost the growth of this region in the Global market during the forecast period 2023-2029.

Asia Pacific is expected to grow rapidly at a CAGR of xx% during the forecast period 2023-2029. This is due to the growing senior population and increased health-care costs. The market demand is expected to be driven by the allocation of a major share of healthcare spending to hospitals and dispensing medicines to the elderly. Higher API production capacity with the world's leading exporters, low-cost manufacturing, a larger patient pool, and more awareness of various diseases and their treatments are all increasing market demand.

The objective of the report is to present a comprehensive analysis of the Global market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The reports also help in understanding the Global market dynamic, structure by analyzing the market segments and project the Global market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market make the report investor’s guide.
API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market Scope: Inquire before



API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market


Base Year
2022
Forecast Period
2023-2029


Historical Data
CAGR
Market Size in 2022
Market Size in 2029


2018 to 2022
6.1%
US$ 2.96 Bn
US$ 4.49 Bn


Segments Covered


by Product
Chondroitin Sulfate
Hyaluronic Acid
Pancreatin
by Type
Pellets
Powder
Others
by End Users
Pharmaceutical Companies
Biotechnology Companies
Others


Regions Covered


North America
United States
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Sweden
Austria
Rest of Europe
Asia Pacific
China
S Korea
Japan
India
Australia
Indonesia
Malaysia
Vietnam
Taiwan
Bangladesh
Pakistan
Rest of APAC
Middle East and Africa
South Africa
GCC
Egypt
Nigeria
Rest of ME&A
South America
Brazil
Argentina
Rest of South America



Key Players
1. Summit Nutritionals International, Inc.
2. Sioux Pharm, Inc.
3. TSI Group Ltd.
4. Shandong Runxin Biotechnology Co., Ltd.
5. ZPD A/S
6. Pacific Rainbow International, Inc.
7. SEIKAGAKU CORPORATION
8. Synutra, Inc.
9. Bioiberica S.A.U.
10. Newgen Biotech USA Inc.
11. Nordmark Arrzneimittel GmbH & Co. KG
12. Qingdao WanTuMing Biological Products Co., Ltd
13. Anthem Biosciences
14. GPT Pharmaceuticals
15. Lee Pharma
16. Beijing Geyuantianrun Biotech

Frequently Asked Questions:

1. Which region has the largest share in Global API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market?
Ans: Asia Pacific region held the highest share in 2022.

2. What is the growth rate of Global API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market?
Ans: The Global market is growing at a CAGR of 6.1% during forecasting period 2023-2029.

3. What is scope of the Global API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) market report?
Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) market?
Ans: The important key players in the Global API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market are – Summit Nutritionals International, Inc., Sioux Pharm, Inc., TSI Group Ltd., Shandong Runxin Biotechnology Co., Ltd., ZPD A/S, Pacific Rainbow International, Inc., SEIKAGAKU CORPORATION, Synutra, Inc., Bioiberica S.A.U., Newgen Biotech USA Inc., Nordmark Arrzneimittel GmbH & Co. KG, Qingdao WanTuMing Biological Products Co., Ltd, Anthem Biosciences, GPT Pharmaceuticals, Lee Pharma, and Beijing Geyuantianrun Biotech

5. What is the study period of this market?
Ans: The Global API (Chondroitin Sulphate, Hyaluronic Acid and Pancreatin) Market is studied from 2022 to 2029.